DOCSLIB.ORG

EPCR Promotes Breast Cancer Progression by Altering SPOCK1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EPCR Promotes Breast Cancer Progression by Altering SPOCK1 Perurena et al. Journal of Hematology & Oncology (2017) 10:23 DOI 10.1186/s13045-017-0399-x RESEARCH Open Access EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growth Naiara Perurena1, Carolina Zandueta1, Susana Martínez-Canarias1, Haritz Moreno1, Silvestre Vicent1,4,5, Ana S. Almeida8, Elisabet Guruceaga2, Roger R. Gomis7, Marta Santisteban6, Mikala Egeblad8, José Hermida3 and Fernando Lecanda1,4,5* Abstract Background: Activated protein C/endothelial protein C receptor (APC/EPCR) axis is physiologically involved in anticoagulant and cytoprotective activities in endothelial cells. Emerging evidence indicates that EPCR also plays a role in breast stemness and human tumorigenesis. Yet, its contribution to breast cancer progression and metastasis has not been elucidated. Methods: Transcriptomic status of EPCR was examined in a cohort of 286 breast cancer patients. Cell growth kinetics was evaluated in control and EPCR and SPARC/osteonectin, Cwcv, and kazal-like domains proteoglycan (SPOCK1/testican 1) silenced breast cancer cells in 2D, 3D, and in co-culture conditions. Orthotopic tumor growth and lung and osseous metastases were evaluated in several human and murine xenograft breast cancer models. Tumor-stroma interactions were further studied in vivo by immunohistochemistry and flow cytometry. An EPCR- induced gene signature was identified by microarray analysis. Results: Analysis of a cohort of breast cancer patients revealed an association of high EPCR levels with adverse clinical outcome. Interestingly, EPCR knockdown did not affect cell growth kinetics in 2D but significantly reduced cell growth in 3D cultures. Using several human and murine xenograft breast cancer models, we showed that EPCR silencing reduced primary tumor growth and secondary outgrowths at metastatic sites, including the skeleton and the lungs. Interestingly, these effects were independent of APC ligand stimulation in vitro and in vivo. Transcriptomic analysis of EPCR-silenced tumors unveiled an effect mediated by matricellular secreted proteoglycan SPOCK1/testican 1. Interestingly, SPOCK1 silencing suppressed in vitro 3D growth. Moreover, SPOCK1 ablation severely decreased orthotopic tumor growth and reduced bone metastatic osteolytic tumors. High SPOCK1 levels were also associated with poor clinical outcome in a subset breast cancer patients. Our results suggest that EPCR through SPOCK1 confers a cell growth advantage in 3D promoting breast tumorigenesis and metastasis. Conclusions: EPCR represents a clinically relevant factor associated with poor outcome and a novel vulnerability to develop combination therapies for breast cancer patients. Keywords: Matricellular, Metastasis, Microenvironment, Sphere cultures, Extracellular matrix * Correspondence: [email protected] 1Adhesion and Metastasis Laboratory, Program Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain 4IdiSNA, Navarra Institute for Health Research, Pamplona, Spain Full list of author information is available at the end of the article © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Perurena et al. Journal of Hematology & Oncology (2017) 10:23 Page 2 of 12 Background APC-EPCR blocking antibodies [18]. In contrast, overex- Endothelial protein C receptor (EPCR) is an endothelial pression of EPCR in MDA-MB-231 cells resulted in re- type 1 transmembrane receptor that enhances the activa- duced final tumor volumes in a xenograft model despite tion of protein C (PC) by the thrombin (IIa)-thrombomo- favoring tumor growth at initial stages [19]. The effect of dulin (TM) complex [1]. EPCR-dissociated activated EPCR at different stages of tumor progression remains protein C (APC) negatively regulates the coagulation poorly defined. process, while EPCR-bound APC induces cytoprotective In this study, we addressed the functional role of signaling through the proteolytic cleavage of protease- EPCR in primary and metastatic tumor growth in breast activated receptor 1 (PAR1), leading to anti-inflammatory cancer using several human and murine xenograft and anti-apoptotic responses [2]. models. We found that EPCR silencing impaired ortho- Recently, research in EPCR has gained considerable topic tumor growth and metastatic activity to the skel- momentum by the identification of new EPCR ligands eton and lungs. Moreover, high EPCR expression levels [2]. An EPCR domain distinct from the APC binding site associated with a poor clinical outcome in a cohort of was shown to interact with a specific T cell antigen breast cancer patients. Furthermore, we showed that receptor with potential implications in immunosurveil- EPCR effects in tumor progression were APC independ- lance of tumors [3]. EPCR was also identified as the ent and were partially mediated by a novel mechanism endothelial receptor for some subtypes of the erythro- involving SPOCK1. Thus, these findings unveil a novel cyte membrane protein 1 (PfEMP1) on the surface of mechanism mediated by EPCR in tumorigenesis and me- the parasite Plasmodium falciparum, mediating its se- tastasis of breast cancer with potential clinical impact on questration in the blood vessels during severe malaria the therapeutic management of breast cancer patients. [4]. FVII/FVIIa has been shown to bind EPCR with a similar affinity as PC/APC [5], whereas the binding of Methods FX/FXa to EPCR remains an open question [6]. Cell lines and reagents Recently, EPCR has been identified as a marker of mul- One thousand eight hundred thirty-three human breast tipotent mouse mammary stem cells (MaSCs). These cancer cell line was a kind gift from Dr. Massagué EPCR+ cells (accounting for 3–7% of basal cells) exhibited (Memorial Sloan-Kettering Cancer Center, NY, USA) [20]. a mesenchymal phenotype and enhanced colony-forming ANV5 murine breast cancer cell line was previously de- abilities [7]. EPCR was also shown to be necessary for cell scribed [21, 22]. APC (Xigris®) was purchased from Eli Lilly organization and growth of human mammary epithelial (Indianapolis, IN, USA). Anti-EPCR antibodies RCR252 cells in 3D cultures [8]. and RCR1 were kindly provided by Dr. Fukudome (Saga In cancer, aberrant expression of EPCR is detected in Medical School, Japan) while 1489 was kindly gifted by tumors of different origin including the lung [9], breast Dr. Esmon (Oklahoma Medical Research Foundation, [10], ovarian [11], colon [12], glioblastoma [13], meso- Oklahoma City, USA). F(ab´)2 fractions of the RCR252 thelioma [14], and leukemia [13]. In lung tumorigenesis, antibody were obtained as previously detailed [9]. APC/EPCR drives an anti-apoptotic program that en- shRNAs cloned into PLKO.1-puro vector and the dows cancer cells with increased survival ability, enhan- empty vector were obtained from Mission® (Sigma- cing their metastatic activity to the skeleton and adrenal Aldrich). glands [9]. Moreover, high expression levels of this single gene at the primary site in early stage lung Cell proliferation assay cancer patients predict the risk of adverse clinical Cell proliferation was assessed using CellTiter 96® progression [9, 15]. AQueous One Solution Cell Proliferation Assay (MTS), In breast cancer patients, tumor cells often dissemin- according to manufacturer’s recommendations (Pro- ate to target sites including the skeleton, lungs, brain, mega). All absorbance values were normalized with the and lymph nodes [16]. This event represents a frequent absorbance values from day 0 (5 h after seeding cells). complication associated with a 5-year survival rate ~25.9%. Recent findings have unveiled novel markers in Cell cycle analysis the primary tumor that predict the development of me- Cell cycle analysis was carried out with Click-iT® EdU tastasis to target organs such as the skeleton [17]. High Flow Cytometry Assay Kit (Invitrogen). Cells were main- EPCR levels have been associated with poor disease pro- tained in culture for 24 or 48 h before adding 10 μM gression in the polyoma middle T (PyMT) breast cancer EdU for 2 h. Next, cells were harvested, fixed in formal- model, closely similar to the luminal B type in humans dehyde (Click-iT® fixative), permeabilized in 1X Click-iT® [18]. Moreover, EPCR+ sorted MDA-MB-231 human saponin-based permeabilization and wash reagent, and breast cancer cells showed stem cell-like properties and incubated with the Click-iT® reaction cocktail for 30 min enhanced tumor-initiating activity, an effect inhibited by at room temperature in the dark. After a washing step, Perurena et al. Journal of Hematology & Oncology (2017) 10:23 Page 3 of 12 cells were incubated with 0.2 μg/μlRNaseA(Sigma- PBS were injected through the tail vein of mice. For BLI, an- Aldrich) for 1 h at room temperature, in the dark. imals were anesthetized and inoculated with 50 μlof 7AAD was added to the tubes 10 min before the acquisi- 15 mg/ml D-luciferin (Promega). Images were taken during tion of cells in a FACSCanto II cytometer (BD Biosci- 1 min
Load more

Recommended publications
  • Cleavage of Lumican by Membrane-Type Matrix Metalloproteinase-1 Abrogates This Proteoglycan-Mediated Suppression of Tumor Cell Colony Formation in Soft Agar
    [CANCER RESEARCH 64, 7058–7064, October 1, 2004] Cleavage of Lumican by Membrane-Type Matrix Metalloproteinase-1 Abrogates This Proteoglycan-Mediated Suppression of Tumor Cell Colony Formation in Soft Agar Yingyi Li,1 Takanori Aoki,1,3 Yuya Mori,1 Munirah Ahmad,1 Hisashi Miyamori,1 Takahisa Takino,1 and Hiroshi Sato1,2 1Department of Molecular Virology and Oncology and 2Center for the Development of Molecular Target Drugs, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan; and 3Daiichi Fine Chemical Co. Ltd., Takaoka, Toyama, Japan ABSTRACT or tumorigenicity in nude mice of rat fibroblast F204 cells trans- formed by K-ras or v-src oncogene (12). The small leucine-rich proteoglycan lumican was identified from a Matrix metalloproteinases (MMPs) are a family of Zn2ϩ-dependent human placenta cDNA library by the expression cloning method as a gene product that interacts with membrane-type matrix metalloproteinase-1 enzymes that are known to cleave extracellular matrix proteins in (MT1-MMP). Coexpression of MT1-MMP with lumican in HEK293T cells normal and pathological conditions (13). Currently, 23 MMP genes reduced the concentration of lumican secreted into culture medium, and have been identified in humans, and they can be subgrouped into this reduction was abolished by addition of the MMP inhibitor BB94. soluble-type and membrane-type MMPs (MT-MMPs; refs. 13, 14). Lumican protein from bovine cornea and recombinant lumican core MMPs are overexpressed in various human malignancies and have protein fused to glutathione S-transferase was shown to be cleaved at been thought to contribute to tumor invasion and metastasis by de- multiple sites by recombinant MT1-MMP.
    [Show full text]
  • Curcumin Alters Gene Expression-Associated DNA Damage, Cell Cycle, Cell Survival and Cell Migration and Invasion in NCI-H460 Human Lung Cancer Cells in Vitro
    ONCOLOGY REPORTS 34: 1853-1874, 2015 Curcumin alters gene expression-associated DNA damage, cell cycle, cell survival and cell migration and invasion in NCI-H460 human lung cancer cells in vitro I-TSANG CHIANG1,2, WEI-SHU WANG3, HSIN-CHUNG LIU4, SU-TSO YANG5, NOU-YING TANG6 and JING-GUNG CHUNG4,7 1Department of Radiation Oncology, National Yang‑Ming University Hospital, Yilan 260; 2Department of Radiological Technology, Central Taiwan University of Science and Technology, Taichung 40601; 3Department of Internal Medicine, National Yang‑Ming University Hospital, Yilan 260; 4Department of Biological Science and Technology, China Medical University, Taichung 404; 5Department of Radiology, China Medical University Hospital, Taichung 404; 6Graduate Institute of Chinese Medicine, China Medical University, Taichung 404; 7Department of Biotechnology, Asia University, Taichung 404, Taiwan, R.O.C. Received March 31, 2015; Accepted June 26, 2015 DOI: 10.3892/or.2015.4159 Abstract. Lung cancer is the most common cause of cancer CARD6, ID1 and ID2 genes, associated with cell survival and mortality and new cases are on the increase worldwide. the BRMS1L, associated with cell migration and invasion. However, the treatment of lung cancer remains unsatisfactory. Additionally, 59 downregulated genes exhibited a >4-fold Curcumin has been shown to induce cell death in many human change, including the DDIT3 gene, associated with DNA cancer cells, including human lung cancer cells. However, the damage; while 97 genes had a >3- to 4-fold change including the effects of curcumin on genetic mechanisms associated with DDIT4 gene, associated with DNA damage; the CCPG1 gene, these actions remain unclear. Curcumin (2 µM) was added associated with cell cycle and 321 genes with a >2- to 3-fold to NCI-H460 human lung cancer cells and the cells were including the GADD45A and CGREF1 genes, associated with incubated for 24 h.
    [Show full text]
  • Appendix 2. Significantly Differentially Regulated Genes in Term Compared with Second Trimester Amniotic Fluid Supernatant
    Appendix 2. Significantly Differentially Regulated Genes in Term Compared With Second Trimester Amniotic Fluid Supernatant Fold Change in term vs second trimester Amniotic Affymetrix Duplicate Fluid Probe ID probes Symbol Entrez Gene Name 1019.9 217059_at D MUC7 mucin 7, secreted 424.5 211735_x_at D SFTPC surfactant protein C 416.2 206835_at STATH statherin 363.4 214387_x_at D SFTPC surfactant protein C 295.5 205982_x_at D SFTPC surfactant protein C 288.7 1553454_at RPTN repetin solute carrier family 34 (sodium 251.3 204124_at SLC34A2 phosphate), member 2 238.9 206786_at HTN3 histatin 3 161.5 220191_at GKN1 gastrokine 1 152.7 223678_s_at D SFTPA2 surfactant protein A2 130.9 207430_s_at D MSMB microseminoprotein, beta- 99.0 214199_at SFTPD surfactant protein D major histocompatibility complex, class II, 96.5 210982_s_at D HLA-DRA DR alpha 96.5 221133_s_at D CLDN18 claudin 18 94.4 238222_at GKN2 gastrokine 2 93.7 1557961_s_at D LOC100127983 uncharacterized LOC100127983 93.1 229584_at LRRK2 leucine-rich repeat kinase 2 HOXD cluster antisense RNA 1 (non- 88.6 242042_s_at D HOXD-AS1 protein coding) 86.0 205569_at LAMP3 lysosomal-associated membrane protein 3 85.4 232698_at BPIFB2 BPI fold containing family B, member 2 84.4 205979_at SCGB2A1 secretoglobin, family 2A, member 1 84.3 230469_at RTKN2 rhotekin 2 82.2 204130_at HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 81.9 222242_s_at KLK5 kallikrein-related peptidase 5 77.0 237281_at AKAP14 A kinase (PRKA) anchor protein 14 76.7 1553602_at MUCL1 mucin-like 1 76.3 216359_at D MUC7 mucin 7,
    [Show full text]
  • MALE Protein Name Accession Number Molecular Weight CP1 CP2 H1 H2 PDAC1 PDAC2 CP Mean H Mean PDAC Mean T-Test PDAC Vs. H T-Test
    MALE t-test t-test Accession Molecular H PDAC PDAC vs. PDAC vs. Protein Name Number Weight CP1 CP2 H1 H2 PDAC1 PDAC2 CP Mean Mean Mean H CP PDAC/H PDAC/CP - 22 kDa protein IPI00219910 22 kDa 7 5 4 8 1 0 6 6 1 0.1126 0.0456 0.1 0.1 - Cold agglutinin FS-1 L-chain (Fragment) IPI00827773 12 kDa 32 39 34 26 53 57 36 30 55 0.0309 0.0388 1.8 1.5 - HRV Fab 027-VL (Fragment) IPI00827643 12 kDa 4 6 0 0 0 0 5 0 0 - 0.0574 - 0.0 - REV25-2 (Fragment) IPI00816794 15 kDa 8 12 5 7 8 9 10 6 8 0.2225 0.3844 1.3 0.8 A1BG Alpha-1B-glycoprotein precursor IPI00022895 54 kDa 115 109 106 112 111 100 112 109 105 0.6497 0.4138 1.0 0.9 A2M Alpha-2-macroglobulin precursor IPI00478003 163 kDa 62 63 86 72 14 18 63 79 16 0.0120 0.0019 0.2 0.3 ABCB1 Multidrug resistance protein 1 IPI00027481 141 kDa 41 46 23 26 52 64 43 25 58 0.0355 0.1660 2.4 1.3 ABHD14B Isoform 1 of Abhydrolase domain-containing proteinIPI00063827 14B 22 kDa 19 15 19 17 15 9 17 18 12 0.2502 0.3306 0.7 0.7 ABP1 Isoform 1 of Amiloride-sensitive amine oxidase [copper-containing]IPI00020982 precursor85 kDa 1 5 8 8 0 0 3 8 0 0.0001 0.2445 0.0 0.0 ACAN aggrecan isoform 2 precursor IPI00027377 250 kDa 38 30 17 28 34 24 34 22 29 0.4877 0.5109 1.3 0.8 ACE Isoform Somatic-1 of Angiotensin-converting enzyme, somaticIPI00437751 isoform precursor150 kDa 48 34 67 56 28 38 41 61 33 0.0600 0.4301 0.5 0.8 ACE2 Isoform 1 of Angiotensin-converting enzyme 2 precursorIPI00465187 92 kDa 11 16 20 30 4 5 13 25 5 0.0557 0.0847 0.2 0.4 ACO1 Cytoplasmic aconitate hydratase IPI00008485 98 kDa 2 2 0 0 0 0 2 0 0 - 0.0081 - 0.0
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Electronic Supplementary Material (ESI) for Analyst. This Journal Is © the Royal Society of Chemistry 2020
    Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2020 Table S1.
    [Show full text]
  • Proteoglycan Form and Function: a Comprehensive Nomenclature of Proteoglycans
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Matrix Biol Manuscript Author . Author manuscript; Manuscript Author available in PMC 2016 May 06. Published in final edited form as: Matrix Biol. 2015 March ; 42: 11–55. doi:10.1016/j.matbio.2015.02.003. Proteoglycan form and function: A comprehensive nomenclature of proteoglycans Renato V. Iozzo1 and Liliana Schaefer2 1Department of Pathology, Anatomy and Cell Biology and the Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA 2Pharmazentrum Frankfurt/ZAFES, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany Abstract We provide a comprehensive classification of the proteoglycan gene families and respective protein cores. This updated nomenclature is based on three criteria: Cellular and subcellular location, overall gene/protein homology, and the utilization of specific protein modules within their respective protein cores. These three signatures were utilized to design four major classes of proteoglycans with distinct forms and functions: the intracellular, cell-surface, pericellular and extracellular proteoglycans. The proposed nomenclature encompasses forty-three distinct proteoglycan-encoding genes and many alternatively-spliced variants. The biological functions of these four proteoglycan families are critically assessed in development, cancer and angiogenesis, and in various acquired and genetic diseases where their expression is aberrant. Keywords Proteoglycan; Glycosaminoglycan; Cancer growth; Angiogenesis; Growth factor modulation Introduction It has been nearly 20 years since the original publication of a comprehensive classification of proteoglycan gene families [1]. For the most part, these classes have been widely accepted. However, a broad and current taxonomy of the various proteoglycan gene families and their products is not available.
    [Show full text]
  • Fibroblasts from the Human Skin Dermo-Hypodermal Junction Are
    cells Article Fibroblasts from the Human Skin Dermo-Hypodermal Junction are Distinct from Dermal Papillary and Reticular Fibroblasts and from Mesenchymal Stem Cells and Exhibit a Specific Molecular Profile Related to Extracellular Matrix Organization and Modeling Valérie Haydont 1,*, Véronique Neiveyans 1, Philippe Perez 1, Élodie Busson 2, 2 1, 3,4,5,6, , Jean-Jacques Lataillade , Daniel Asselineau y and Nicolas O. Fortunel y * 1 Advanced Research, L’Oréal Research and Innovation, 93600 Aulnay-sous-Bois, France; [email protected] (V.N.); [email protected] (P.P.); [email protected] (D.A.) 2 Department of Medical and Surgical Assistance to the Armed Forces, French Forces Biomedical Research Institute (IRBA), 91223 CEDEX Brétigny sur Orge, France; [email protected] (É.B.); [email protected] (J.-J.L.) 3 Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse, Institut de Biologie François Jacob, CEA/DRF/IRCM, 91000 Evry, France 4 INSERM U967, 92260 Fontenay-aux-Roses, France 5 Université Paris-Diderot, 75013 Paris 7, France 6 Université Paris-Saclay, 78140 Paris 11, France * Correspondence: [email protected] (V.H.); [email protected] (N.O.F.); Tel.: +33-1-48-68-96-00 (V.H.); +33-1-60-87-34-92 or +33-1-60-87-34-98 (N.O.F.) These authors contributed equally to the work. y Received: 15 December 2019; Accepted: 24 January 2020; Published: 5 February 2020 Abstract: Human skin dermis contains fibroblast subpopulations in which characterization is crucial due to their roles in extracellular matrix (ECM) biology.
    [Show full text]
  • Gene Expression Alterations in Salivary Gland Epithelia of Sjögren's
    www.nature.com/scientificreports OPEN Gene expression alterations in salivary gland epithelia of Sjögren’s syndrome patients are associated with clinical and histopathological manifestations Ariana Dela Cruz1,7, Vinay Kartha2,7, Andrew Tilston‑Lunel3,7, Rongjuan Mi1,3, Taylor L. Reynolds4, Michael Mingueneau4, Stefano Monti2, Janicke L. Jensen5, Kathrine Skarstein6, Xaralabos Varelas3* & Maria A. Kukuruzinska1* Sjögren’s syndrome (SS) is a complex autoimmune disease associated with lymphocytic infltration and secretory dysfunction of salivary and lacrimal glands. Although the etiology of SS remains unclear, evidence suggests that epithelial damage of the glands elicits immune and fbrotic responses in SS. To defne molecular changes underlying epithelial tissue damage in SS, we laser capture microdissected (LCM) labial salivary gland epithelia from 8 SS and 8 non‑SS controls for analysis by RNA sequencing (RNAseq). Computational interrogation of gene expression signatures revealed that, in addition to a division of SS and non‑SS samples, there was a potential intermediate state overlapping clustering of SS and non‑SS samples. Diferential expression analysis uncovered signaling events likely associated with distinct SS pathogenesis. Notable signals included the enrichment of IFN‑γ and JAK/STAT‑ regulated genes, and the induction of genes encoding secreted factors, such as LTF, BMP3, and MMP7, implicated in immune responses, matrix remodeling and tissue destruction. Identifcation of gene expression signatures of salivary epithelia associated with mixed clinical and histopathological characteristics suggests that SS pathology may be defned by distinct molecular subtypes. We conclude that gene expression changes arising in the damaged salivary epithelia may ofer novel insights into the signals contributing to SS development and progression.
    [Show full text]
  • 3364.Full.Pdf
    [CANCER RESEARCH 63, 3364–3369, June 15, 2003] Testican 2 Abrogates Inhibition of Membrane-type Matrix Metalloproteinases by Other Testican Family Proteins1 Mitsutoshi Nakada,2 Hisashi Miyamori,2 Junkoh Yamashita, and Hiroshi Sato3 Department of Molecular Virology and Oncology [M. N., H. M., H. S.], Center for the Development of Molecular Target Drugs, Cancer Research Institute [H. S.], Department of Neurosurgery, Division of Neuroscience, Graduate School of Medical Science [M. N., J. Y.], Kanazawa University, Ishikawa 920-0934, Japan ABSTRACT activation of pro-MMP-2 is a common functional role proposed for all of the MT-MMPs (4–8), expression of MT1-MMP most closely Testican family proteins are putative extracellular heparan/chondroitin correlates with invasive phenotype of human tumors (9–13). sulfate proteoglycans of unknown function. We identified recently N-Tes, Testican was first defined as an unnamed chondroitin/heparan which is a product of testican 3 splicing variant gene, as an inhibitor of membrane-type matrix metalloproteinases (MT-MMPs). The inhibitory sulfate proteoglycan in seminal plasma (14). Corresponding cDNAs function is common among testican family members except for testican 2, were isolated from human testis libraries, and the deduced protein was which was shown to uniquely abolish inhibition of MT1-MMP- or MT3- named testican (15). To date 3 members of the testican family were MMP-mediated pro-MMP-2 activation by other testican family members. identified by cDNA cloning, with deduced amino acid homologies of Testican 2 inactivates N-Tes by binding to the COOH-terminal extracel- 42%, 51%, and 44% for testican 1/testican 2, testican 1/testican 3, and lular calcium-binding domain of N-Tes through its NH2-terminal unique testican 2/testican 3, respectively (15–17).
    [Show full text]
  • Ncomms2128.Pdf
    ARTICLE Received 10 Jul 2012 | Accepted 6 Sep 2012 | Published 9 Oct 2012 DOI: 10.1038/ncomms2128 A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis Nathan E. Reticker-Flynn1,2, David F. Braga Malta1,2,3,4, Monte M. Winslow1,5, John M. Lamar1, Mary J. Xu2, Gregory H. Underhill1,6, Richard O. Hynes1,7,8, Tyler E. Jacks1,7,8,9 & Sangeeta N. Bhatia1,2,8,10,11 Extracellular matrix interactions have essential roles in normal physiology and many pathological processes. Although the importance of extracellular matrix interactions in metastasis is well documented, systematic approaches to identify their roles in distinct stages of tumorigenesis have not been described. Here we report a novel-screening platform capable of measuring phenotypic responses to combinations of extracellular matrix molecules. Using a genetic mouse model of lung adenocarcinoma, we measure the extracellular matrix-dependent adhesion of tumour-derived cells. Hierarchical clustering of the adhesion profiles differentiates metastatic cell lines from primary tumour lines. Furthermore, we uncovered that metastatic cells selectively associate with fibronectin when in combination with galectin-3, galectin-8 or laminin. We show that these molecules correlate with human disease and that their interactions are mediated in part by α3β1 integrin. Thus, our platform allowed us to interrogate interactions between metastatic cells and their microenvironments, and identified extracellular matrix and integrin interactions that could serve as therapeutic targets. 1 David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA. 2 Harvard- MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
    [Show full text]